Serological diagnosis of whooping cough using immunoblot methods

Česká verzia

Authors: I. Lochman ^1,2; L. Pokorná ²; H. Mertová ²
Authors place of work: Spadia Lab, a. s., Ostrava ¹; Test Line Clinical Diagnostics, Brno ²
Published in the journal: Epidemiol. Mikrobiol. Imunol. 66, 2017, č. 3, s. 107-114
Category: Původní práce

Summary

The aim of study:
The aim of this study was to challenge the conclusion presented in the current recommendations of the EU Perstrain Group (European group of reference laboratories) [17] that immunoblotting methods are not appropriate serological methods for the diagnosis of pertussis because their results cannot be quantified. To consider benefits of these methods for the diagnosis of Bordetella infections was another aim of this work.

Material and methods:
The residual sera from routine testing intended for disposal and results of routine tests for Bordetella infections performed in Spadia Lab in 2015 and 2016 were used in this study. The test samples were anonymized. Standard commercial ELISA and immunoblot kits were used for analyses.

Results and conclusions:
Using the TestLine Clinical Diagnostics Company kits, we have shown that, contrary to the conclusion of the EU Perstrain Group, quantification of the immunoblot results is possible and that these methods can improve the diagnosis of Bordetella infections, ultimately making it more effective.

KEYWORDS:
whooping cough – serological diagnosis – immunoblot

Zdroje

1. Bordetella pertussis taxonomy. Dostupné na www: https://microbewiki.kenyon.edu/index.php/Bordetella_pertussis.

2. Breakwell L, Kelso P, Finley C, et al. Pertussis Vaccine Effectiveness in the Setting of Pertactin-Deficient Pertussis. Pediatrics, 2016;137(5). pii: e20153973. doi: 10.1542/peds.2015-3973. Epub 2016 Apr 12.

3. Boursaux-Eude C, Guiso N. Polymorphism of repeated regions of pertactin in Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica. Infect Immun, 2000; 68(8): 4815–4817.

4. Carbonetti NH. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol, 2010;5: 455–469.

5. Cherry JD. Adult pertussis in the pre- and post-vaccine eras: lifelong vaccine-induced immunity? Expert Rev Vaccines, 2014;13(9): 1073–1080.

6. Cherry JD, Paddock CD. Pathogenesis and histopathology of pertussis: implications for immunization. Expert Rev Vaccines, 2014;13(9): 1115–1123.

7. Cherry JD. Tetanus-diphtheria-pertussis immunization in pregnant women and the prevention of pertussis in young infants. Clin Infect Dis, 2015;60(3): 338–340.

8. Cherry JD, Xing DXL, Newland P, et al. Determination of Serum Antibody to Bordetella pertussis Adenylate Cyclase Toxin in Vaccinated and Unvaccinated Children and in Children and Adults with Pertussis. Clin Infect Dis, 2004;38: 502–507.

9. Cundell DR, Kanthakumar K, Taylor GW, et al. Effect of Tracheal Cytotoxin from Bordetella pertussis on Human Neutrophil Function In Vitro. Infection and Immunity, 1994; 62(2): 639–643.

10. The human microbiome: Me, myself, us. The Economist, Aug 18th 2012, Print Edition. Dostupné na www: http://www.economist.com/node/21560523/print.

11. Edwards KM, Berbers GA. Immune responses to pertussis vaccines and disease. J Infect Dis, 2014;209(Suppl 1): S10–15.

12. Fabiánová K, Zavadilová J. Aktualizovaná doporučení pro laboratorní diagnostiku pertuse a parapertuse. Zprávy CEM (SZÚ, Praha), 2011;20(4): 142–144.

13. Fabiálnová K. Pertuse. Alergie, 2015;17(4): 249–254.

14. Fabiánová K. Polymorfismus Bordetella pertusis a vývoj nových očkovacích látek proti pertusi. Vakcinologie, 2016;10(4): 150–154.

15. Finney LJ, Ritchie A, Pollard E, et al. Lower airway colonization and inflammatory response in COPD: a focus on Haemophilus influenzae. International Journal of COPD, 2014;9: 1119–1132.

16. Furuya-Kanamori L, Maarquess J, Yakob L, et al. Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications. BMC Infectious Diseases, 2015;15: 516–527.

17. Guiso N, Berbers G, Fry NK, et al. EU Pertstrain group. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis, 2011;30(3): 307–312.

18. Goodwin MStM, Weiss AA. Adenylate Cyclase Toxin Is Critical for Colonization and Pertussis Toxin Is Critical for Lethal Infection by Bordetella pertussis in Infant Mice. Infection and Immunity, 1990;58(10): 3445–3447.

19. Halperin SA. Serologic and Molecular Tools for Diagnosing Bordetella pertussis Infection. In Manual of Molecular and Clinical Laboratory Immunology, 7thEdition, Detrick B, Hamilton RG, Folds JD editors, ASM Press, 2006, p. 540–546.

20. Leng Q, Bentwich Z. Beyond self and nonself: fuzzy recognition of the immune system. Scand J Immunol, 2002;56(3): 224–232.

21. Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis, 1990;161(3): 480–486.

22. Martin C, Etxaniz A, Uribe KB, et al. Adenylate Cyclase Toxin promotes bacterial internalization into non phagocytic cells. Sci Rep, 2015;5: 13774. doi: 10.1038/srep13774.

23. Mattoo S, Cherry JD. Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies. Clinical Microbiology Reviews, 2005;18(2): 326–382.

24. NCBI Taxonomy, Bordetella pertussis 18323. Dostupné na www: http://www.ncbi.nlm.nih.gov/taxonomy.

25. Pabst O, Cerovic V, Hornef M. Secretory IgA in the Coordination of Establishment and Maintenance of the Microbiota. Trends in Immunology, 2016;37(5): 287–296.

26. Pawloski LC, Queenan AM, Cassiday PK, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the US in 2012. Clin. Vaccine Immunol, 2014;21(2): 119–125.

27. Riggs MM, Sethi AK, Zabarsky TF, et al. Asymptomatic Carriers Are a Potential Source for Transmission of Epidemic and Nonepidemic Clostridium difficile Strains among Long-Term Care Facility Residents. Clin Infect Dis, 2007;45: 992–998.

28. Sebo P, Osicka R, Masin J. Adenylate cyclase toxin-hemolysis relevance for pertussis vaccines. Expert Rev Vaccines, 2014;13(10): 1215–1227.

29. Theriot CM, Young VB. Interactions between the Gastrointestinal Microbiome and Clostridium difficile. Annu Rev Microbiol, 2015;69: 445–461.

30. Villarino RR, Hasan S, Faé K, et al. Bordetella pertussis filamentous hemagglutinin itself does not trigger anti-inflammatory interleukin-10 production by human dendritic cells. Int J Med Mictobiol, 2016;306(1): 38–47.

31. Warfel JM, Zimmerman LI, Merkel TJ. Comparison of Three Whole--Cell Pertussis Vaccines in the Baboon Model of Pertussis. Clinical and Vaccine Immunology, 2016;23(1): 47–54.

32. Warfel JM, Edwards KM. Pertussis vaccines and the challenge of inducing durable immunity. Curr Opin Immunol, 2015;35: 48–54.

33. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J, 2005;25(5 Suppl): S58–61.

34. Williams MM, Sen K, Weigand MR, et al. CDC Pertussis Working Group: Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin. Emerg Infect Dis, 2016;22(2): 319–322.

35. Witt MA, Arias L, Katz PH, et al. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis, 2013;56(9): 1248–1254.

36. Zavadilová J, Fabiánová K, Maixnerová M. Doporučení pro laboratorní diagnostiku dávivého kašle. Zprávy epidemiologie a mikrobiologie (SZÚ, Praha), 2009;18(1): 24–25.

37. Zavadilová J, Lžičařová D, Musílek M, Křížová P, Fabiánová K. Antigenic variability of Bordetella pertussis strains isolated in 1967–2010 in the Czech Republic-possible explanation for the rise in cases of pertussis? Epidemiol Mikrobiol Imunol, 2015;64(3): 130–138.

38. Ziklo N, Huston WM, Hockong JS, Timms P. Chlamydia trachomatis Genital Tract Infections: When Host Immune Response and the Microbiome Collide. Trends Microbiol, 2016;24(9): 750–765.

39. Zinkernagel RM. Uncertainties – discrepancies in immunology. Immunology Reviews, 2002;185: 103–125.

40. Zlamy M. Rediscovering Pertussis. Frontiers in Pediatrics, 2016;4(Article 52): 1–10.